| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
61,390,000 |
| Market
Cap: |
422.36(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$6.15 - $24.1 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Replimune Group is a clinical-stage biotechnology company focused on applying its capabilities in the field of oncolytic immunotherapy to transform the lives of cancer patients through its tumor-directed oncolytic immunotherapies. Co.'s RPx product candidates in its development pipeline include: RP1, which is a selectively replicating version of herpes simplex virus 1 that expresses GALV-GP R(-) and human GM-CSF; RP2, which expresses an anti-CTLA-4 antibody-like protein intended to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3, which expresses immune-activating proteins that stimulate T cells, in addition to anti-CTLA-4 and GALV-GP R(-).
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
12,568 |
159,192 |
218,988 |
| Total Sell Value |
$0 |
$137,243 |
$3,016,052 |
$4,045,075 |
| Total People Sold |
0 |
2 |
9 |
9 |
| Total Sell Transactions |
0 |
2 |
17 |
25 |
| End Date |
2024-02-08 |
2023-11-07 |
2023-05-09 |
2022-05-09 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Slattery Joseph P |
Director |
– • – |
2020-12-08 |
4 |
S |
$46.00 |
$239,200 |
D/D |
(5,200) |
6,667 |
|
39% |
|
| Slattery Joseph P |
Director |
– • – |
2020-12-08 |
4 |
OE |
$3.30 |
$17,160 |
D/D |
5,200 |
11,867 |
|
- |
|
| Dhingra Kapil |
Director |
– • – |
2020-12-07 |
4 |
S |
$45.09 |
$1,822,395 |
D/D |
(40,000) |
0 |
|
36% |
|
| Dhingra Kapil |
Director |
– • – |
2020-12-07 |
4 |
OE |
$1.75 |
$70,000 |
D/D |
40,000 |
40,000 |
|
- |
|
| Rhodes Jason P |
Director |
– • – |
2020-12-07 |
4 |
AS |
$45.45 |
$3,120,459 |
I/I |
(67,890) |
35,709 |
|
-36% |
|
| Love Colin |
Chief Operating Officer |
• – – |
2020-11-16 |
4 |
AS |
$44.41 |
$673,649 |
D/D |
(15,000) |
1,006,524 |
|
-31% |
|
| Esposito Pamela |
Chief Business Officer |
• – – |
2020-10-14 |
4 |
AS |
$30.15 |
$526,410 |
D/D |
(16,000) |
112,700 |
|
0% |
|
| Esposito Pamela |
Chief Business Officer |
• – – |
2020-10-14 |
4 |
OE |
$1.01 |
$16,160 |
D/D |
16,000 |
128,700 |
|
- |
|
| Love Colin |
Chief Operating Officer |
• – – |
2020-09-15 |
4 |
AS |
$23.09 |
$359,487 |
D/D |
(15,000) |
1,021,524 |
|
65% |
|
| Atlas Venture Fund X, L.p. |
10% Owner |
– – • |
2020-09-15 |
4 |
AS |
$0.00 |
$0 |
D/D |
(445,339) |
2,486,296 |
|
65% |
|
| Esposito Pamela |
Chief Business Officer |
• – – |
2020-08-31 |
4 |
AS |
$27.05 |
$135,250 |
D/D |
(5,000) |
112,700 |
|
57% |
|
| Esposito Pamela |
Chief Business Officer |
• – – |
2020-08-31 |
4 |
OE |
$1.01 |
$5,050 |
D/D |
5,000 |
117,700 |
|
- |
|
| Love Colin |
Chief Operating Officer |
• – – |
2020-08-17 |
4 |
AS |
$23.19 |
$351,555 |
D/D |
(15,000) |
1,036,524 |
|
68% |
|
| Pirzkall Andrea |
Chief Medical OfficerOfficer |
• – – |
2020-07-20 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
1,000 |
|
130% |
|
| Coffin Robert |
President & Chief R&D Officer |
• • – |
2020-07-09 |
4 |
AS |
$21.02 |
$3,757,295 |
D/D |
(169,750) |
2,024,118 |
|
121% |
|
| Atlas Venture Fund X, L.p. |
10% Owner |
– – • |
2020-07-02 |
4 |
AS |
$0.00 |
$0 |
D/D |
(445,339) |
2,931,635 |
|
99% |
|
| Atlas Venture Fund X, L.p. |
10% Owner |
– – • |
2020-06-16 |
4 |
AS |
$0.00 |
$0 |
D/D |
(445,339) |
3,376,974 |
|
110% |
|
| Coffin Robert |
Pres & Chief Res & Dev Officer |
• • – |
2020-02-20 |
4 |
AS |
$17.04 |
$413,220 |
D/D |
(24,250) |
2,193,868 |
|
48% |
|
| Coffin Robert |
Pres & Chief Res & Dev Officer |
• • – |
2020-02-12 |
4 |
AS |
$17.03 |
$826,198 |
D/D |
(48,500) |
2,218,118 |
|
21% |
|
| Esposito Pamela |
Chief Business Officer |
• – – |
2019-12-20 |
4 |
OE |
$1.75 |
$44,975 |
D/D |
25,700 |
112,700 |
|
- |
|
| Kaufman Howard |
Chief Medical Officer |
• – – |
2019-11-26 |
4 |
OE |
$3.30 |
$191,621 |
D/D |
58,067 |
58,067 |
|
- |
|
| Atlas Venture Associates Opportunity I, Llc |
|
– – – |
2019-11-18 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
1,100,000 |
|
- |
|
| Rhodes Jason P |
Director |
– • – |
2019-11-18 |
4 |
B |
$13.61 |
$14,971,000 |
I/I |
1,100,000 |
1,100,000 |
2.1 |
- |
|
| Stampacchia Otello |
Director |
– • • |
2019-11-18 |
4 |
B |
$13.61 |
$2,994,200 |
D/D |
220,000 |
5,328,939 |
3.92 |
- |
|
| Astley-Sparke Philip |
Executive Chairman |
• • – |
2019-11-06 |
4 |
AS |
$17.00 |
$493,290 |
D/D |
(29,000) |
1,355,297 |
|
- |
|
172 Records found
|
|
Page 6 of 7 |
|
|
0.13 (1.85%) 
